Boston Scientific Corp (BSX) Buy, Sell or Hold

Boston Scientific Corp (BSX)

44.24

+1.49 (3.47%)

as of Nov 9, 2026, 8:10:00 pm Market Closed.

102 watching

HOLD

An extraordinarily well-run company. Great organic growth. A leader in the cardiac rhythm management, and have done that principally organically. The new management in 2012 streamlined operations, became very efficient and enhanced margins on the back of that. This is a company that he wants to continue to own.

BUY

Thinks this is a good time to be investing in manufacturers of medical devices. There is a whole seasonality that starts in January with a little bit of a pickup in February. They tend to peak every year right around August/September, so there is a bit of time to ride this out.

DON'T BUY

In the last 9 months they had their heart defibrillator withdrawn from the US market because of FDA problems. Would steer clear of this one.

DON'T BUY

Had an earnings disappointment. FMV trend is sharply down. When factoring in analysts forecasts, the FMV is about $12.30.

BUY ON WEAKNESS

Will have to go to $20.50 before it has a bounce. Has a model price of $31.95 which is a 37/38% differential.

BUY

In a lawsuit with Johnson and Johnson (JNJ-N), so a lot depends on who wins the case. Their product works better than JNJ and he continues to like it.

BUY

Things look good for them. Won a patent case against Johnson & Johnson (JNJ-N).

WEAK BUY

It's close to a buy. Model price is $32.09 which is a 5% differential.

TOP PICK

"We really like Boston [Scientific]" Thinks they have a better product then the competitor. Had a series of recalls, but have been able to gain back the marketshare. But the stock didn't recover as well. So is now undervalued.

DON'T BUY

Long term chart shows that it made a base, had a fantastic rise to $45 in 2002/2003, very little top formation and now we are in a downtrend. Stock has now fallen below its 200 day moving average.

BUY

A good company. Their coated stents is a terrific product. Up against Johnson & Johnson in the stent business, but they are holding their own. A good buy at this price.

WEAK BUY

Stock has dropped because of the recall of their stent. Price is reasonably attractive.

TOP PICK

A company that focuses on earnings. A tremendous new product that should give a nice boost to their income.

DON'T BUY

Its drug coated stent is driving the price up, but other competitors are lurking on the horizon. Not cheap.

TOP PICK

Likes this sector. Strong and persistant growth. Revenue and earnings growth has been very persistant. Good products. Buy on pull backs.

Showing 61 to 75 of 75 entries

Most Recent Experts

Jim Cramer - Mad Money

CNBC

Mike Philbrick

ReSolve Asset Management

Jeff Parent B. Eng. FCSI CIM

Castlemoore Inc.

The Weekly Buzzing Stocks by Billy Kawasaki

Stockchase

Rebecca Teltscher

Newhaven Asset Management

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

Boston Scientific Corp (BSX)